Virus Clinical Trials

393 recruitingLast updated: June 18, 2026

There are 393 actively recruiting virus clinical trials across 91 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, New York, New York, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Virus Trials at a Glance

393 actively recruiting trials for virus are listed on ClinicalTrialsFinder across 6 cities in 91 countries. The largest study group is Not Applicable with 77 trials, with the heaviest enrollment activity in Houston, New York, and Atlanta. Lead sponsors running virus studies include National Cancer Institute (NCI), Assistance Publique - Hôpitaux de Paris, and National Institute of Allergy and Infectious Diseases (NIAID).

Treatments under study

About Virus Clinical Trials

Looking for clinical trials for Virus? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Virus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 393 trials

Recruiting
Not Applicable

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

Cervical CarcinomaHuman Papillomavirus Infection
National Cancer Institute (NCI)500 enrolled18 locationsNCT07281430
Recruiting
Phase 1

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Human Papillomavirus-Related Carcinoma
National Cancer Institute (NCI)18 enrolled5 locationsNCT05985681
Recruiting

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Castleman's DiseaseKaposi's SarcomaHuman Immunodeficiency Virus+1 more
National Cancer Institute (NCI)280 enrolled1 locationNCT03300830
Recruiting

Comparison Diagnostic Tests for the Diagnosis of CYTOmegalovirus Organ Disease in Patients With intestinalBOweL Diseases

Cytomegalovirus (CMV)Inflammatory Bowel Disease (IBD)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled1 locationNCT06793124
Recruiting

Infant RSV Immunity Study

Respiratory Synctial VirusAsthma Childhood
University of British Columbia300 enrolled1 locationNCT07653347
Recruiting
Phase 1

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Cytomegalovirus Prophylaxis
Merck Sharp & Dohme LLC40 enrolled17 locationsNCT07199465
Recruiting
Phase 3

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Coronavirus Disease (COVID-19)
Merck Sharp & Dohme LLC3,082 enrolled224 locationsNCT06667700
Recruiting
Phase 2

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Merkel Cell CarcinomaMalignant NeoplasmAcquired Immunodeficiency Syndrome+5 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02479698
Recruiting
Phase 2

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

Squamous Cell Carcinoma of the Head and NeckDrug TherapyOropharynx+2 more
National Cancer Institute (NCI)70 enrolled1 locationNCT06223568
Recruiting

Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study

Human Immunodeficiency Virus (HIV) -1 infectionHIV-1 Subtype A6 InfectionHIV-1 Subtype B Infection+1 more
Pomeranian Medical University Szczecin250 enrolled7 locationsNCT07370649
Recruiting
Phase 3

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Cytomegalovirus InfectionsKidney Transplant InfectionPancreas Transplant
University of Wisconsin, Madison90 enrolled1 locationNCT06407232
Recruiting
Phase 2

Boosting Olfactory and Sensory Training Study (BOOST)

HIV (Human Immunodeficiency Virus)
University of Alabama at Birmingham80 enrolled1 locationNCT07221123
Recruiting
Not Applicable

Unidos Contra el VPH

Cervical CancersHuman Papilloma Virus (HPV)
University of Texas at Austin735 enrolled1 locationNCT06825689
Recruiting
Phase 2

A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease

Respiratory Syncytial Virus Infections
Shionogi192 enrolled73 locationsNCT07214571
Recruiting

HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks

Human Papilloma Virus
University of Edinburgh500 enrolled1 locationNCT06414057
Recruiting
Phase 1

R-MVST Cells for Treatment of Viral Infections

Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490
Recruiting
Phase 1Phase 2

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

Systemic Inflammatory Response SyndromeSARS CoV-2Respiratory distress syndrome+2 more
PEACHES BIOTECH50 enrolled3 locationsNCT06684379
Recruiting
Phase 2

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

LymphomaEpstein-Barr Virus InfectionsLymphoproliferative Disorder+1 more
National Cancer Institute (NCI)40 enrolled1 locationNCT03258567
Recruiting

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

SepsisSystemic Inflammatory Response SyndromeInfection, Bacterial+5 more
Michigan State University2,500 enrolled2 locationsNCT01904188
Recruiting

Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

Cytomegalovirus InfectionsMaternal Primary Cytomegalovirus Infection
Assistance Publique - Hôpitaux de Paris491 enrolled3 locationsNCT06694428